Williamson, James C5; Scheipers, Peter3; Schwämmle, Veit5; Zibert, John Robert4; Beck, Hans Christian6; Jensen, Ole N5
1 Department of Biochemistry and Molecular Biology, Faculty of Science, SDU2 Clinical Biochemistry, Department of Clinical Research, Det Sundhedsvidenskabelige Fakultet, SDU3 unknown4 Neuro- og Sansefag5 Department of Biochemistry and Molecular Biology, Faculty of Science, SDU6 Clinical Biochemistry, Department of Clinical Research, Det Sundhedsvidenskabelige Fakultet, SDU
The discovery of plasma biomarkers for psoriasis vulgaris may aid clinicians in disease grading and monitoring of treatment response. We have therefore developed a proteomics/mass spectrometry based workflow which enables biomarker discovery from psoriasis patient samples. We have utilised keratome skin biopsy, which results in reduced cellular complexity compared to punch biopsy. Furthermore, we applied short term ex vivo culture in order to enrich for a "secretome" sub-proteome reflective of the disease and enriched in potential biomarkers. Using these sample preparation techniques we performed a quantitative proteomics screen of four patients with psoriasis using stable isotope dimethyl labelling and identified over 50 proteins consistently altered in abundance in psoriasis lesional versus non-lesional skin. This includes several canonical psoriasis related proteins (e.g. S100A7 [Psoriasin] and FABP5 [Epidermal Fatty Acid Binding Protein]) and more than 30 novel alterations. From this disease localised dataset we further assessed several proteins as potential biomarkers in the plasma of patients with psoriasis versus healthy controls utilising selected reaction monitoring mass spectrometry (SRM-MS/MS).